title: Pseudoprogression: relevance with respect to treatment of high-grade gliomas.
abstract: The post-treatment imaging assessment of high-grade gliomas remains challenging notwithstanding the increased utilization of advanced MRI and PET imaging. Several post-treatment imaging entities are recognized including: late-delayed radiation injury, including radionecrosis mimicking tumor progression; early-delayed (within 6 months of temozolomide-based chemoradiation) post-treatment radiographic changes, herein referred to as pseudoprogression (the subject of this review); early post-treatment changes following local glioma therapy (i.e. biodegradable BCNU wafer implantation or stereotactic radiotherapy); and pseudoresponse, seen following treatment with angiogenic inhibition based therapy such as bevacizumab. A literature review searched specifically for "pseudoprogression" within the last 5 years (2005-2010). Approximately 24 recent papers were identified and reviewed in detail. Eight small population-based studies demonstrate 26-58% (median 49%) of glioblastoma patients treated with chemoradiotherapy manifest early disease progression at first post-radiotherapy imaging. Patients with early radiographic disease progression continued on planned therapy, and a median of 38% (range 28-66%) showed radiographic improvement or stabilization and were defined retrospectively as manifesting pseudoprogression. In conclusion, pseudoprogression is a frequent early post-treatment imaging change that at present is not easily differentiated from tumor progression by anatomic or physiologic brain imaging. Consequently, an operational definition of pseudoprogression has been adopted by the Response Assessment in Neuro-Oncology Working Group wherein either the index (i.e. target) lesion stabilizes or diminishes in size on continued post-radiation (temozolomide) therapy as determined by follow-up radiologic imaging.
authors: Department of Radiology, University of Washington, Seattle, USA.
authors: James
authors: J
authors: Fink
authors: Donald
authors: D
authors: Born
authors: Marc C
authors: MC
authors: Chamberlain
references: Neuro Oncol. 2009 Aug;11(4):430-6
references: 19289492
references: J Clin Oncol. 1990 Jul;8(7):1277-80
references: 2358840
references: Clin Neurol Neurosurg. 2007 Jan;109(1):106-10
references: 16793199
references: J Clin Oncol. 2005 Jun 20;23(18):4127-36
references: 15961760
references: J Neurooncol. 2004 Oct;70(1):49-58
references: 15527107
references: Cancer. 2010 Sep 1;116(17):3988-99
references: 20564141
references: J Clin Oncol. 2010 Apr 10;28(11):1963-72
references: 20231676
references: Arch Pathol Lab Med. 2009 Jul;133(7):1062-77
references: 19642733
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: Neurosurgery. 2005 Sep;57(3):505-11; discussion 505-11
references: 16145529
references: Curr Opin Oncol. 2010 Nov;22(6):598-603
references: 20689430
references: Radiology. 1982 Sep;144(4):813-7
references: 6287519
references: Nat Med. 2009 May;15(5):572-6
references: 19377487
references: J Clin Oncol. 2010 May 1;28(13):2293-9
references: 20368564
references: AJNR Am J Neuroradiol. 2008 Mar;29(3):419-24
references: 18272557
references: J Neurooncol. 2007 Aug;84(1):63-9
references: 17619225
references: Mol Imaging Biol. 2009 Sep-Oct;11(5):343-55
references: 19326172
references: Cancer. 2008 Jul 15;113(2):405-10
references: 18484594
references: J Nucl Med. 2006 Oct;47(10):1612-21
references: 17015896
references: Can J Neurol Sci. 2010 Jan;37(1):36-42
references: 20169771
references: J Clin Oncol. 2007 Oct 20;25(30):4714-21
references: 17947718
references: J Neurosurg. 1979 May;50(5):624-8
references: 430157
references: Can J Neurol Sci. 2009 Sep;36(5):617-22
references: 19831132
references: Hum Pathol. 2006 Mar;37(3):272-82
references: 16613322
references: J Neurooncol. 2007 Mar;82(1):81-3
references: 16944309
references: AJNR Am J Neuroradiol. 1998 Mar;19(3):407-13
references: 9541290
references: J Nucl Med. 2008 May;49(5):694-9
references: 18413375
references: AJNR Am J Neuroradiol. 2000 May;21(5):901-9
references: 10815666
references: Anticancer Res. 2009 Jul;29(7):2607-10
references: 19596935
references: AJNR Am J Neuroradiol. 2004 Feb;25(2):201-9
references: 14970018
references: J Neurosurg. 1977 Sep;47(3):329-35
references: 894339
references: Acta Neuropathol. 2006 Mar;111(3):197-212
references: 16463065
references: AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8
references: 19056837
references: AJNR Am J Neuroradiol. 2010 Jun;31(6):1049-54
references: 20110377
references: Neurology. 2004 Aug 10;63(3):535-7
references: 15304589
references: Radiology. 2010 Nov;257(2):342-52
references: 20829544
references: J Nucl Med. 2004 Oct;45(10):1653-9
references: 15471829
references: Nat Clin Pract Oncol. 2008 Nov;5(11):634-44
references: 18711427
references: J Clin Oncol. 2008 May 1;26(13):2192-7
references: 18445844
references: AJNR Am J Neuroradiol. 2001 Aug;22(7):1316-24
references: 11498420
references: Curr Opin Neurol. 2009 Dec;22(6):633-8
references: 19770760